3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30
Myelodysplastic Syndromes
26
Hematologic Neoplasms
20
Lymphoma, Non-Hodgkin
19
Multiple Myeloma
18
Lymphoma
18
Recurrence
15
Lymphoma, B-Cell
14
Lymphoma, Large B-Cell, Diffuse
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Burkitt Lymphoma
12
Breast Neoplasms
11
Pancreatic Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Follicular
10
Neoplasm Metastasis
9
Melanoma
9
Leukemia, Myelomonocytic, Chronic
9
Myeloproliferative Disorders
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Leukemia, Biphenotypic, Acute
7
Leukemia
7
Hodgkin Disease
7
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Osteosarcoma
6
Interventions
Pemetrexed
4
Cisplatin
4
pembrolizumab
3
Nivolumab
3
Interleukin-2
3
Carboplatin
3
atezolizumab
2
aldesleukin
2
Pharmaceutical Preparations
2
Ipilimumab
2
olaparib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
Thoracoscopy
1
Thoracic Surgery, Video-Assisted
1
Surgery, Computer-Assisted
1
Proton Therapy
1
Platinum
1
Paclitaxel
1
Injections
1
Influenza Vaccines
1
Indocyanine Green
1
In Situ Hybridization, Fluorescence
1
Cyclophosphamide
1
Combined Modality Therapy
1
Cerebral Decortication
1
Brentuximab Vedotin
1
Blood Component Removal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Mesothelioma, Malignant
×
fludarabine
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled